131 related articles for article (PubMed ID: 38082188)
1. Prognostic role of pathologic status other than complete response after neoadjuvant therapy followed by surgery in esophageal squamous cell carcinoma.
Park SY; Lee J; Oh D; Sun JM; Yun J; Jeon YJ; Cho JH; Choi YS; Zo JI; Shim YM; Kim HK
Esophagus; 2024 Jan; 21(1):51-57. PubMed ID: 38082188
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
[TBL] [Abstract][Full Text] [Related]
3. Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
Yun JK; Kim Y; Lee GD; Choi S; Kim YH; Kim DK; Park SI; Kim HR
Cancer Med; 2022 Oct; 11(19):3623-3632. PubMed ID: 35434935
[TBL] [Abstract][Full Text] [Related]
4. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
[TBL] [Abstract][Full Text] [Related]
5. The Role of Adjuvant Chemotherapy after Neoadjuvant Chemoradiotherapy Followed by Surgery in Patients with Esophageal Squamous Cell Carcinoma.
Park SY; Kim HK; Jeon YJ; Lee J; Cho JH; Choi YS; Shim YM; Zo JI
Cancer Res Treat; 2023 Oct; 55(4):1231-1239. PubMed ID: 37114475
[TBL] [Abstract][Full Text] [Related]
6. ypT0N+: the unusual patient with pathological complete tumor response but with residual lymph node disease after neoadjuvant chemoradiation for esophageal cancer, what's up?
Depypere LP; Vervloet G; Lerut T; Moons J; De Hertogh G; Sagaert X; Coosemans W; Van Veer H; Nafteux PR
J Thorac Dis; 2018 May; 10(5):2771-2778. PubMed ID: 29997939
[TBL] [Abstract][Full Text] [Related]
7. Proposed modification of the eighth edition of the AJCC-ypTNM staging system of esophageal squamous cell cancer treated with neoadjuvant chemotherapy: Unification of the AJCC staging system and the Japanese classification.
Oshikiri T; Goto H; Kato T; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Fujino Y; Tominaga M; Kakeji Y
Eur J Surg Oncol; 2022 Aug; 48(8):1760-1767. PubMed ID: 35094909
[TBL] [Abstract][Full Text] [Related]
8. Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: a population-based study.
Al-Kaabi A; van der Post RS; van der Werf LR; Wijnhoven BPL; Rosman C; Hulshof MCCM; van Laarhoven HWM; Verhoeven RHA; Siersema PD
Acta Oncol; 2021 Apr; 60(4):497-504. PubMed ID: 33491513
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.
Rice TW; Ishwaran H; Kelsen DP; Hofstetter WL; Apperson-Hansen C; Blackstone EH;
Dis Esophagus; 2016 Nov; 29(8):906-912. PubMed ID: 27905170
[TBL] [Abstract][Full Text] [Related]
10. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
[TBL] [Abstract][Full Text] [Related]
11. Residual lymph node status is an independent prognostic factor in esophageal squamous cell Carcinoma with pathologic T0 after preoperative radiotherapy.
Wang Q; Yu S; Xiao Z; Liu X; Zhang W; Zhang X; He J; Sun K; Xu T; Feng Q; Zhou Z; Wang L; Yin W
Radiat Oncol; 2015 Jul; 10():142. PubMed ID: 26159510
[TBL] [Abstract][Full Text] [Related]
12. ypT0N+ status in oesophageal cancer patients: Location of residual metastatic lymph nodes with regard to the neoadjuvant radiation field.
Schurink B; Seesing MFJ; Goense L; Mook S; Brosens LAA; Mohammad NH; Ruurda JP; Roeling TAP; Bleys RLAW; van Hillegersberg R
Eur J Surg Oncol; 2019 Mar; 45(3):454-459. PubMed ID: 30503227
[TBL] [Abstract][Full Text] [Related]
13. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
14. SUV
Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
World J Surg Oncol; 2021 Apr; 19(1):105. PubMed ID: 33836789
[TBL] [Abstract][Full Text] [Related]
15. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status.
Kim MP; Correa AM; Lee J; Rice DC; Roth JA; Mehran RJ; Walsh GL; Ajani JA; Maru DM; Chang JY; Marom EM; Macapinlac HA; Lee JH; Vaporciyan AA; Rice T; Swisher SG; Hofstetter WL
Ann Thorac Surg; 2010 Sep; 90(3):884-90; discussion 890-1. PubMed ID: 20732513
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
17. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
[TBL] [Abstract][Full Text] [Related]
18. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of patients with esophageal squamous cell carcinoma who achieved a pathological complete response in the primary lesion by neoadjuvant treatment: a Japanese nationwide cohort study.
Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Kakeji Y; Kono K; Kitagawa Y; Takeuchi H
Esophagus; 2024 Jan; 21(1):2-10. PubMed ID: 37999900
[TBL] [Abstract][Full Text] [Related]
20. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
